Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06567743 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
A Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer, sponsored by CG Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
- 20
- Study locations
NCT06567743 is a Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer that is actively recruiting participants, run by CG Oncology. The registered enrollment target is 325 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT06567743, a Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer, is actively recruiting participants, sponsored by CG Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Conditions Studied
Interventions
- DRUG Cretostimogene Grenadenorepvec
Study Locations (20)
California
- Michael G Oefelein, MD Clinical Trials - Bakersfield
- Genesis Research (Greater Los Angeles) - Los Alamitos
- Advanced Urology - Los Angeles
- Urology Center of Southern California - Murrieta
- University of California, Irvine - Orange
- Om research - San Diego
- University of Southern California - San Diego
- Genesis Research (Greater Los Angeles) - Torrance
Florida
- University of Florida - Gainesville
- Mayo Clinic Florida - Jacksonville
- Advanced Urology Institute (Solaris) - Largo
- Advanced Urology Institute - Oxford
- Advanced Urology Institute - Tallahassee (Solaris) - Tallahassee
Arizona
- Mayo Clinic Arizona - Phoenix
- Arizona Urology Specialty - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Arkansas Urology - Little Rock
Colorado
- Colorado Urology - Lakewood
- Urology Associates, Lone Tree - Lone Tree
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06567743
The ClinicalTrials.gov registry entry for NCT06567743 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CG Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-Risk Non-Muscle-Invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cretostimogene Grenadenorepvec is the first listed.
NCT06567743 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06567743 about?
NCT06567743 is a clinical study titled "Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC". This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
What is the current status of trial NCT06567743?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2024-09-16. Estimated completion is 2027-12-30.
What conditions does trial NCT06567743 study?
This clinical trial studies the following conditions: High-Risk Non-Muscle-Invasive Bladder Cancer.
What interventions are being tested in trial NCT06567743?
The interventions under investigation include: Cretostimogene Grenadenorepvec (DRUG).
Who is sponsoring clinical trial NCT06567743?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06567743 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-Risk Non-Muscle-Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.